ArticleBMC cancer2016
Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Advancing understanding of autoimmune diseases and lung cancer: trends, themes, and future directions.Discover oncology · 2025Article
- Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases.RMD open · 2023Article
- Survival in elderly patients with breast cancer with and without autoimmune disease.Cancer medicine · 2023Article
- Clinical features and prognosis of lung cancer in patients with connective tissue diseases: a retrospective cohort study.Frontiers in oncology · 2023Article
- Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival.Lupus · 2022Article
- Epidemiology and Treatment of Systemic Sclerosis in Korea.Journal of rheumatic diseases · 2022Review
- Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease.JTO clinical and research reports · 2022Article
- Lung Cancer Survival in Patients With Autoimmune Disease.JAMA network open · 2020Article
- The Association of Autoimmune Disease With Lung Cancer Survival.JAMA network open · 2020Article
- Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study.Annals of translational medicine · 2020Article
- Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.Annals of the rheumatic diseases · 2020Article
- The utility of histological subtype for predicting survival of lung cancer patients with rheumatoid arthritis.Translational cancer research · 2020Article
- Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010-2018.Journal of clinical medicine · 2019Article
- The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival.Archives of rheumatology · 2019Article
- The association between infection incidence and autoimmune diseases in breast cancer patients after anti-cancer treatment.Journal of Cancer · 2019Article
- Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion.Oncology letters · 2019Article
- Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.Clinical rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundTo compare the outcomes of gastric, colon, lung, and breast cancer patients with and without rheumatic diseases (RD).
methodsThis retrospective study compared the cancer survival rates of a cohort of 122 cancer patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), or systemic sclerosis with that of a cohort of 366 age-, sex-, and, cancer type-matched patients without RD who received medical care from 2000 to 2014. Staging, comorbidities, and functional status were ascertained. Survival was compared using the Kaplan-Meier method. Relative risk of death was estimated as a hazard ratio (HR) using Cox regression analysis.
resultsThe mean age of the RD patients at the time of cancer diagnosis was 58.7 ± 11.5 years. The overall survival rate of gastric cancer patients did not differ between the cohorts. The survival of lung or breast cancer was worse in patients with RA or DM/PM than in those without RD (all, p < 0.05). After adjusting for cancer stage, comorbidity index, performance status and age at the time of cancer diagnosis (as well as interstitial lung disease for lung cancer group), the mortality rate among lung cancer patients with RA was significantly higher (HR, 1.81; 95 % CI, 1.03-3.18) than that of lung cancer patients without RD, whereas SSc was associated with decreased mortality of lung cancer (HR, 0.16; 95 % CI, 0.04-0.58). DM/PM were associated with increased mortality of breast cancer patients (HR, 297.39; 95 % CI, 4.24-20842.33).
conclusionsRA and DM/PM seemed to be associated with a higher mortality in patients with lung or breast cancers, whereas SSc seemed to be associated with decreased mortality in patients with lung cancer. It is warranted to explore the survival effect of tailored cancer treatments according to specific RD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.